Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients

American Surgeon

Volumn 76, Issue 6, 2010, Pages 563-570

  Arnold, Joshua D ^a   Dart, Benjamin W ^a   Barker, Donald E ^a   Maxwell, Robert A ^a   Burkholder, Hans C ^a   Mejia, Vicente A ^a   Smith, Philip W ^a   Longley, Joy M ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; ANTICOAGULANT AGENT;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLUNT TRAUMA; COMPUTER ASSISTED TOMOGRAPHY; COST CONTROL; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG COST; DRUG EFFICACY; FEMALE; GLASGOW COMA SCALE; HEAD INJURY; HEMATOMA; HIP FRACTURE; HOSPITAL ADMISSION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PELVIS; PRACTICE GUIDELINE; RESUSCITATION; RISK FACTOR; SCREENING; SPINAL CORD INJURY; SUBDURAL HEMATOMA; THROMBOSIS PREVENTION; TRAUMATIC BRAIN INJURY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; ECONOMICS; INJURY; MIDDLE AGED; RETROSPECTIVE STUDY; UNITED STATES; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COST SAVINGS; ENOXAPARIN; FEMALE; HEAD INJURIES, CLOSED; HEPARIN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SPINAL CORD INJURIES; TENNESSEE; VENOUS THROMBOSIS; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 77953640315     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(suppl):381S-453S.
2. Heit JACA, Anderson FA Jr., VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US [Abstract]). Blood 2005;106:910.
3. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009;145: 286-95.
4. Wakefield TW, Caprini J, Comerota AJ. Thromboembolic diseases. Curr Probl Surg 2008;45:844-99.
5. Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002;16:155-65.
6. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl): 338S-400S.
7. Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma 2002;53:142-64.
8. Johanson NA, Lachiewicz PF, Lieberman JR, et al. American academy of orthopaedic surgeons clinical practice guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am 2009; 91:1756-7.
9. The Joint Commission and the Centers for Medicare & Medicaid Services. Specifications Manual for National Hospital Inpatient Quality Measures. Version 2.6b. Available at: www. jointcommission.org/ PerformanceMeasurement/Current+NHQM+ Manual/htm. Accessed June10, 2009.
10. Deitelzweig SB, Lin J, Hussein M, et al. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis? J Thromb Thrombolysis 2009 Oct 1 [Epub ahead of print].
11. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(suppl): 141S-59S.
12. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990;16(suppl):12-8.
13. Johnson EA, Mulloy B. The molecular-weight range of mucosal-heparin preparations. Carbohydr Res 1976;51:119-27.
14. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976;9:575-83.
15. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53: 691-5.
16. Barzu T, Molho P, Tobelem G, et al. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985;845:196-203.
17. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982;31: 104-13.
18. Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta Med Scand 1963;173:619-30.
19. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 1988;543:65-72.
20. Bradbrook ID, Magnani HN, Moelker HC, et al. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987;23:667-75.
21. Velmahos GC. The current status of thromboprophylaxis after trauma: a story of confusion and uncertainty. Am Surg 2006; 72:757-63.
22. Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report - part I: analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 2000;49:132-8; discussion 139.
23. Geerts WH, Jay RM, Code KI, et al. A comparison of lowdose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-7.
24. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-73.
25. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227-40.
26. Wolf H, Encke A, Haas S, et al. Comparison of the efficacy and safety of Sandoz low molecular weight heparin and unfractionated heparin: interim analysis of a multicenter trial. Semin Thromb Hemost 1991;17:343-6.
27. Haas S, Wolf H, Kakkar AK, et al. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost 2005;94:814-9.
28. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 1996;26:127-39.
29. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996;26(suppl 2):49-56.
30. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly inpatients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996;76:529-34.
31. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-21.
32. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma 2003;54:1116-24; discussion 1125-6.
33. Passman M. Mandated quality measures and economic implications of venous thromboembolism prevention and management. Am J Surg 2010;199(suppl):S21-S31.
34. MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and postthrombotic syndrome. Am J Health Syst Pharm 2006;63(suppl 6): S5-15.
35. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
36. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117: 19-25.
37. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.